Abstract
Autologous, in vitro-expanded tumor-infiltrating lymphocytes (TIL) have been successfully used for treatment of melanoma patients. Expansion of TIL from tumors is usually performed in two steps. The details of the procedure differ between different laboratories, but the general concept remains the same. In the first step, small fragments of a tumor are placed in culture medium containing one or more T cell stimulating growth factors. Here the most common protocol using interleukin (IL)-2 is described. The length of the first step is flexible to allow generation of enough cell to start the second step of the procedure. The second step is a so-called rapid expansion protocol (REP) where harvested TIL from the first step are induced to massive proliferation via triggering of their T cell receptor (TCR) complex in presence of an excess of feeder cells and, again, T cell stimulating growth factors. This second expansion step is usually around 2 weeks in length. Here will be described a REP that uses soluble anti-CD3 antibodies for TCR triggering, irradiated peripheral blood mononuclear cells (PBMC) as feeder cells, and IL-2 as the T cell growth factor. Furthermore, the described protocol utilizes gas-permeable cell culture flasks that yield large number of cells similar to conventional bioreactors but using standard laboratory equipment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rosenberg SA, Packard BS, Aebersold PM et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676–1680. https://doi.org/10.1056/NEJM198812223192527
Rosenberg SA, Yannelli JR, Yang JC et al (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86(15):1159–1166
Besser MJ, Shapira-Frommer R, Schachter J (2015) Tumor-infiltrating lymphocytes: clinical experience. Cancer J 21(6):465–469. https://doi.org/10.1097/PPO.0000000000000154
Besser MJ, Shapira-Frommer R, Treves AJ et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16(9):2646–2655. https://doi.org/10.1158/1078-0432.CCR-10-0041
Ellebaek E, Iversen TZ, Junker N et al (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169. https://doi.org/10.1186/1479-5876-10-169
Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257(1):56–71. https://doi.org/10.1111/imr.12132
Pilon-Thomas S, Kuhn L, Ellwanger S et al (2012) Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35(8):615–620. https://doi.org/10.1097/CJI.0b013e31826e8f5f
Poschke I, Lövgren T, Adamson L et al (2014) A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 63(10):1061–1071. https://doi.org/10.1007/s00262-014-1575-2
Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770. https://doi.org/10.1158/1078-0432.CCR-12-1177
Bajgain P, Mucharla R, Wilson J et al (2014) Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev 1:14015. https://doi.org/10.1038/mtm.2014.15
Forget MA, Haymaker C, Dennison JB et al (2016) The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology 5(2):e1057386. https://doi.org/10.1080/2162402X.2015.1057386
Forget MA, Malu S, Liu H et al (2014) Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 37(9):448–460. https://doi.org/10.1097/CJI.0000000000000056
Jin J, Sabatino M, Somerville R et al (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35(3):283–292. https://doi.org/10.1097/CJI.0b013e31824e801f
Alvarez-Fernandez C, Escriba-Garcia L, Vidal S et al (2016) A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy. J Transl Med 14(1):214. https://doi.org/10.1186/s12967-016-0973-y
Cieri N, Camisa B, Cocchiarella F et al (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4):573–584. https://doi.org/10.1182/blood-2012-05-431718
Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101(7):1969–1974. https://doi.org/10.1073/pnas.0307298101
Li Y, Bleakley M, Yee C (2005) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175(4):2261–2269
Redeker A, Arens R (2016) Improving adoptive T Cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination. Front Immunol 7:345. https://doi.org/10.3389/fimmu.2016.00345
Chacon JA, Pilon-Thomas S, Sarnaik AA et al (2013) Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2(9):e25581. https://doi.org/10.4161/onci.25581
Chacon JA, Wu RC, Sukhumalchandra P et al (2013) Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8(4):e60031. https://doi.org/10.1371/journal.pone.0060031
Donia M, Larsen SM, Met O et al (2014) Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy 16(8):1117–1120. https://doi.org/10.1016/j.jcyt.2014.02.004
Klapper JA, Thomasian AA, Smith DM et al (2009) Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345(1-2):90–99. https://doi.org/10.1016/j.jim.2009.04.009
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wickström, S., Lövgren, T. (2019). Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors. In: Pico de Coaña, Y. (eds) Immune Checkpoint Blockade. Methods in Molecular Biology, vol 1913. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8979-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8979-9_7
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8978-2
Online ISBN: 978-1-4939-8979-9
eBook Packages: Springer Protocols